← 返回

Baroreflex Activation Therapy in Patients with Heart Failure with a Reduced Ejection Fraction.

Baroreflex Activation Therapy in Patients with Heart Failure with a Reduced Ejection Fraction.

期刊: Cardiac electrophysiology clinics 日期: 2026-09-01 PMID: 42580795 DOI: 10.1016/j.ccep.2026.06.008 浏览: 19
作者: Ruddy JM, Kroman A, Baicu CF, Zile MR
JM, R., A, K., CF, B., & MR, Z. (2026). Baroreflex Activation Therapy in Patients with Heart Failure with a Reduced Ejection Fraction.. Cardiac electrophysiology clinics. https://doi.org/10.1016/j.ccep.2026.06.008
JM R, A K, CF B, MR Z. Baroreflex Activation Therapy in Patients with Heart Failure with a Reduced Ejection Fraction.. Cardiac electrophysiology clinics. 2026; doi: 10.1016/j.ccep.2026.06.008
JM R, A K, CF B, et al. Baroreflex Activation Therapy in Patients with Heart Failure with a Reduced Ejection Fraction.[J]. Cardiac electrophysiology clinics. 2026. DOI: 10.1016/j.ccep.2026.06.008.
@article{jm2026,
  author = {Ruddy JM and Kroman A and Baicu CF and Zile MR},
  title = {Baroreflex Activation Therapy in Patients with Heart Failure with a Reduced Ejection Fraction.},
  journal = {Cardiac electrophysiology clinics},
  year = {2026},
  doi = {10.1016/j.ccep.2026.06.008},
  note = {PMID: 42580795},
}
TY  - JOUR
AU  - Ruddy JM
AU  - Kroman A
AU  - Baicu CF
AU  - Zile MR
TI  - Baroreflex Activation Therapy in Patients with Heart Failure with a Reduced Ejection Fraction.
T2  - Cardiac electrophysiology clinics
PY  - 2026
DO  - 10.1016/j.ccep.2026.06.008
AN  - PMID:42580795
ER  - 

摘要

A randomized, controlled trial of baroreflex activation therapy (BAT) in patients with heart failure and reduced ejection fraction demonstrated that BAT was safe and significantly improved patient-centered symptomatic outcomes, increasing exercise capacity, improving quality of life, decreasing n-terminal pro B-type natriuretic peptide (NT-proBNP), and improving functional class. BAT was approved by the FDA for improvement of symptoms of heart failure for patients who remain symptomatic despite treatment with guideline-directed management, are New York Heart Association Class III or Class II (with a recent history of Class III), have a left ventricular ejection fraction ≤ 35%, an NT-proBNP < 1600 pg/mL and excluding patients indicated for cardiac resynchronization therapy.

AI 智能解读

相关文献

返回分类: 心衰 查看原文 (DOI)
已选择 0 篇文献